Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care

A European survey

Daniela Bertens, Stephanie Vos, Patrick Kehoe, Henrike Wolf, Flavio Nobili, Alexandre Mendonça, Ineke Van Rossum, Jacub Hort, Jose Luis Molinuevo, Michael Heneka, Ronald Carl Petersen, Philip Scheltens, Pieter Jelle Visser

Research output: Contribution to journalArticle

Abstract

Introduction: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. Methods: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. Results: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. Conclusions: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.

Original languageEnglish (US)
Article number74
JournalAlzheimer's Research and Therapy
Volume11
Issue number1
DOIs
StatePublished - Aug 22 2019

Fingerprint

Alzheimer Disease
Neurology
Cognitive Dysfunction
Surveys and Questionnaires
Risk Reduction Behavior
Research

Keywords

  • MCI
  • MCI due to AD
  • Prodromal AD
  • Questionnaire
  • Survey

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care : A European survey. / Bertens, Daniela; Vos, Stephanie; Kehoe, Patrick; Wolf, Henrike; Nobili, Flavio; Mendonça, Alexandre; Van Rossum, Ineke; Hort, Jacub; Molinuevo, Jose Luis; Heneka, Michael; Petersen, Ronald Carl; Scheltens, Philip; Visser, Pieter Jelle.

In: Alzheimer's Research and Therapy, Vol. 11, No. 1, 74, 22.08.2019.

Research output: Contribution to journalArticle

Bertens, D, Vos, S, Kehoe, P, Wolf, H, Nobili, F, Mendonça, A, Van Rossum, I, Hort, J, Molinuevo, JL, Heneka, M, Petersen, RC, Scheltens, P & Visser, PJ 2019, 'Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: A European survey', Alzheimer's Research and Therapy, vol. 11, no. 1, 74. https://doi.org/10.1186/s13195-019-0525-9
Bertens, Daniela ; Vos, Stephanie ; Kehoe, Patrick ; Wolf, Henrike ; Nobili, Flavio ; Mendonça, Alexandre ; Van Rossum, Ineke ; Hort, Jacub ; Molinuevo, Jose Luis ; Heneka, Michael ; Petersen, Ronald Carl ; Scheltens, Philip ; Visser, Pieter Jelle. / Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care : A European survey. In: Alzheimer's Research and Therapy. 2019 ; Vol. 11, No. 1.
@article{f1f4225143d8441eb4a8ed6a29d2462d,
title = "Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: A European survey",
abstract = "Introduction: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. Methods: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. Results: Almost all respondents (92{\%}) used the MCI diagnosis in clinical practice. Over 80{\%} of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68{\%} of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86{\%}), increased possibilities to provide counseling (51{\%}), facilitation of follow-up planning (48{\%}), start of medical intervention (49{\%}), and response to patients' wish for a diagnosis (41{\%}). Over 70{\%} of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. Conclusions: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.",
keywords = "MCI, MCI due to AD, Prodromal AD, Questionnaire, Survey",
author = "Daniela Bertens and Stephanie Vos and Patrick Kehoe and Henrike Wolf and Flavio Nobili and Alexandre Mendon{\cc}a and {Van Rossum}, Ineke and Jacub Hort and Molinuevo, {Jose Luis} and Michael Heneka and Petersen, {Ronald Carl} and Philip Scheltens and Visser, {Pieter Jelle}",
year = "2019",
month = "8",
day = "22",
doi = "10.1186/s13195-019-0525-9",
language = "English (US)",
volume = "11",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care

T2 - A European survey

AU - Bertens, Daniela

AU - Vos, Stephanie

AU - Kehoe, Patrick

AU - Wolf, Henrike

AU - Nobili, Flavio

AU - Mendonça, Alexandre

AU - Van Rossum, Ineke

AU - Hort, Jacub

AU - Molinuevo, Jose Luis

AU - Heneka, Michael

AU - Petersen, Ronald Carl

AU - Scheltens, Philip

AU - Visser, Pieter Jelle

PY - 2019/8/22

Y1 - 2019/8/22

N2 - Introduction: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. Methods: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. Results: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. Conclusions: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.

AB - Introduction: The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. Methods: An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. Results: Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. Conclusions: The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.

KW - MCI

KW - MCI due to AD

KW - Prodromal AD

KW - Questionnaire

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85071222866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071222866&partnerID=8YFLogxK

U2 - 10.1186/s13195-019-0525-9

DO - 10.1186/s13195-019-0525-9

M3 - Article

VL - 11

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 74

ER -